Inhibition of β-lactamase function by de novo designed peptide

Area of Science:

• Microbiology
• Biophysics
• Drug Discovery

Background:

• Antimicrobial resistance (AMR) is a global health crisis, driven by mechanisms like beta-lactamase enzymes.
• Existing beta-lactamase inhibitors are limited, particularly against metallo-beta-lactamases (Class B).
• Novel strategies are crucial to develop effective antibacterial treatments against multidrug-resistant bacteria.

Purpose of the Study:

• To investigate the Resonant Recognition Model (RRM) as a novel approach for designing antimicrobial resistance inhibitors.
• To design peptide inhibitors targeting specific beta-lactamase enzymes using the RRM.

Main Methods:

• Utilized the Resonant Recognition Model (RRM) to analyze structure-function relationships of 22 beta-lactamase proteins.
• Designed 30-mer peptides with specific RRM spectral periodicities to act as beta-lactamase inhibitors.
• Tested designed peptides for inhibitory activity against bacterial beta-lactamases.

Main Results:

• Achieved 100% inhibition of Class A beta-lactamases from Escherichia coli and Enterobacter cloacae.
• Demonstrated the efficacy of RRM-designed peptides as potent inhibitors.
• Showcased the potential of RRM in designing inhibitors for various beta-lactamase classes.

Conclusions:

• The Resonant Recognition Model (RRM) shows promise for designing targeted beta-lactamase inhibitors.
• This approach offers a new strategy to combat antimicrobial resistance.
• RRM-based inhibitor design could address limitations of current therapeutic options.